Molecular Partners Ag (MOLN) Operating Income (2022 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Operating Income of -$20.9 million for Q2 2025, down 18.4% year-over-year from -$25.6 million in Q2 2024, and down 18.4% quarter-over-quarter from -$17.7 million in Q2 2024.
Molecular Partners Ag (MOLN) Operating Income (2022 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Operating Income for 4 consecutive years, with -$20.9 million the latest figure, recorded in Q2 2025.
- In Q2 2025, Operating Income fell 18.4% year-over-year to -$20.9 million; the TTM figure through Jun 2025 stood at $102.1 million (changed N/A YoY), while the FY2025 annual figure was -$72.7 million, down 4.07% from the prior year.
- Operating Income eased to -$20.9 million in Q2 2025 per MOLN's latest filing, from -$17.7 million in the prior quarter.
- Across five years, Operating Income topped out at $158.4 million in Q2 2022 and bottomed at -$20.9 million in Q2 2025.
- Historically, Operating Income has averaged $25.5 million across 4 years, with a median of -$17.7 million in 2023.
- Annual changes were most pronounced in 2023 — Operating Income tumbled 111.15% — and 2024, when it dropped 0.01%.
- Molecular Partners Ag's Operating Income stood at $158.4 million in 2022, then sank by 111.15% to -$17.7 million in 2023, then declined by 0.01% to -$17.7 million in 2024, then retreated by 18.4% to -$20.9 million in 2025.
- Business Quant data shows MOLN's Operating Income at -$20.9 million in Q2 2025, -$17.7 million in Q2 2024, and -$17.7 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.70 Bn | 131.85 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.36 Bn | 60.18 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 59.15 Bn | 54.01 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.88 Bn | 28.57 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | 133.12 Mn |
| 10 | Molecular Partners Ag | 163.25 Mn | 163.25 Mn | - | -17,166.77 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17,166.77 |
| Dec 31, 2025 | 56,858.03 |
| Sep 30, 2025 | -15,057.57 |
| Jun 30, 2025 | -20.92 Mn |
| Jun 30, 2024 | -17.67 Mn |
| Jun 30, 2023 | -17.66 Mn |
| Jun 30, 2022 | 158.39 Mn |